Markets

NuCana Says European Patent Office Grants Patent Covering Composition Of Matter For NUC-7738

Sep 30, 2026 · 08:03 AM ET· updated 1h ago

NuCana plc (NASDAQ:NCNA) ("NuCana" or the "Company") announced that the European Patent Office ("EPO") has granted an important patent covering the composition of matter for NUC-7738.This patent

Why It Matters

NuCana got official approval from Europe to protect their new drug NUC-7738. This legal protection means competitors cannot copy this medicine in Europe for many years.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

NCNA1.33

+0.12 (+9.92%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.